| Proliferating cell nuclear antigen (pcna) and C-erbb-2 oncoprotein in breast-carcinoma with correlations to histopathological parameters and prognosis. | breast, |
| Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. | breast, |
| Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. | breast, |
| c-erbB-2 protein expression in astrocytic tumors of the brain. | brain, |
| Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. | breast, |
| The c-erb B-2 proto-oncogene in human pancreatic cancer. | pancreatic, |
| Immunohistochemical analysis of c-erbB-2 oncogene product and epidermal growth factor receptor expression in human urinary bladder carcinomas. | bladder, |
| [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)]. | breast, |
| Expression of the Adenovirus Early Gene 1A Transcription-Repression Domain Alone Downregulates HER2 and Results in the Death of Human Breast Cancer Cells Upregulated for the HER2 Proto-Oncogene. | breast, |
| Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women. | breast, |
| C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast. | breast, |
| Circulating levels of HER-2/neu oncoprotein in breast cancer. | breast, |
| c-erbB-2 oncogene expression in ovarian cancer. | ovarian, |
| HER-2/neu oncogene and estrogen receptor expression in non small cell lung cancer patients. | lung, |
| Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells. | breast, |
| There is early involvement of HER2 dysregulation (amplification and protein overexpression) in both gastric (intestinal-type) and Barrett_s oncogenesis. | gastric, |
| Leptin and HER-2 are associated with gastric cancer progression and prognosis of patients. | gastric, |
| Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. | lung, |
| Negative estrogen-receptor invasive breast carcinoma: mammographic aspects, correlations with HER2/neu oncoprotein status. | breast, |
| The evaluation of the immunoexpression of Her2/neu oncoprotein in ductal carcinoma in situ in association with invasive ductal carcinoma of the breast. | breast, |